

World Journal of *Hepatology*

World J Hepatol 2017 July 8; 9(19): 833-866



**MINIREVIEWS**

- 833 Opportunities for treatment of the hepatitis C virus-infected patient with chronic kidney disease

Ladino M, Pedraza F, Roth D

- 840 Imaging guided percutaneous interventions in hepatic dome lesions: Tips and tricks

Kambadakone A, Baliyan V, Kordbacheh H, Uppot RN, Thabet A, Gervais DA, Arellano RS

ORIGINAL ARTICLE**Retrospective Cohort Study**

- 850 Improved Hepascore in hepatitis C predicts reversal in risk of adverse outcome

Jeffrey AW, Huang Y, de Boer WB, Adams LA, MacQuillan G, Speers D, Joseph J, Jeffrey GP

Prospective Study

- 857 Is hepatic steatosis associated with left ventricular mass index increase in the general population?

Piontek K, Schmidt CO, Baumeister SE, Lerch MM, Mayerle J, Dörr M, Felix SB, Völzke H

ABOUT COVER

Editorial Board Member of *World Journal of Hepatology*, Veronika Lukacs-Kornek, MD, PhD, Assistant Professor, Department of Internal Medicine II, Saarland University Hospital, 66424 Homburg, Germany

AIM AND SCOPE

World Journal of Hepatology (*World J Hepatol*, *WJH*, online ISSN 1948-5182, DOI: 10.4254), is a peer-reviewed open access academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

WJH covers topics concerning liver biology/pathology, cirrhosis and its complications, liver fibrosis, liver failure, portal hypertension, hepatitis B and C and inflammatory disorders, steatohepatitis and metabolic liver disease, hepatocellular carcinoma, biliary tract disease, autoimmune disease, cholestatic and biliary disease, transplantation, genetics, epidemiology, microbiology, molecular and cell biology, nutrition, geriatric and pediatric hepatology, diagnosis and screening, endoscopy, imaging, and advanced technology. Priority publication will be given to articles concerning diagnosis and treatment of hepatology diseases. The following aspects are covered: Clinical diagnosis, laboratory diagnosis, differential diagnosis, imaging tests, pathological diagnosis, molecular biological diagnosis, immunological diagnosis, genetic diagnosis, functional diagnostics, and physical diagnosis; and comprehensive therapy, drug therapy, surgical therapy, interventional treatment, minimally invasive therapy, and robot-assisted therapy.

We encourage authors to submit their manuscripts to *WJH*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great basic and clinical significance.

INDEXING/ABSTRACTING

World Journal of Hepatology is now indexed in Emerging Sources Citation Index (Web of Science), PubMed, PubMed Central, and Scopus.

FLYLEAF

I-IV Editorial Board

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Xiang Li*
Responsible Electronic Editor: *Dan Li*
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Fung-Fung Ji*
Proofing Editorial Office Director: *Jin-Lei Wang*

NAME OF JOURNAL
World Journal of Hepatology

ISSN
ISSN 1948-5182 (online)

LAUNCH DATE
October 31, 2009

FREQUENCY
36 Issues/Year (8th, 18th, and 28th of each month)

EDITORS-IN-CHIEF
Clara Balsano, PhD, Professor, Department of Biomedicine, Institute of Molecular Biology and Pathology, Rome 00161, Italy

Wan-Long Chuang, MD, PhD, Doctor, Professor, Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan

EDITORIAL BOARD MEMBERS
All editorial board members resources online at <http://www.wjgnet.com>

www.wjgnet.com/1948-5182/editorialboard.htm

EDITORIAL OFFICE
Xiu-Xia Song, Director
World Journal of Hepatology
Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: editorialoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>

PUBLISHER
Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: bpgoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>

PUBLICATION DATE
July 8, 2017

COPYRIGHT
© 2017 Baishideng Publishing Group Inc. Articles published by this Open Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT
All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

INSTRUCTIONS TO AUTHORS
<http://www.wjgnet.com/bpg/gerinfo/204>

ONLINE SUBMISSION
<http://www.f6publishing.com>

Prospective Study

Is hepatic steatosis associated with left ventricular mass index increase in the general population?

Katharina Piontek, Carsten O Schmidt, Sebastian E Baumeister, Markus M Lerch, Julia Mayerle, Marcus Dörr, Stephan B Felix, Henry Völzke

Katharina Piontek, Institute for Medical Psychology, University Medicine Greifswald, 17489 Greifswald, Germany

Katharina Piontek, Carsten O Schmidt, Sebastian E Baumeister, Henry Völzke, Institute for Community Medicine, University Medicine Greifswald, 17489 Greifswald, Germany

Markus M Lerch, Julia Mayerle, Department of Medicine A, University Medicine Greifswald, 17489 Greifswald, Germany

Marcus Dörr, Stephan B Felix, Department of Cardiology, University Medicine Greifswald, 17489 Greifswald, Germany

Marcus Dörr, Stephan B Felix, Henry Völzke, German Centre for Cardiovascular Research, Partner site Greifswald, 17489 Greifswald, Germany

Author contributions: Piontek K and Schmidt CO contributed equally to this work; Völzke H designed the research; Schmidt CO analysed the data; Piontek K wrote the paper; Baumeister SE, Lerch MM, Mayerle J, Dörr M and Felix SB contributed to writing the paper; all authors read and approved the final manuscript.

Supported by Bundesministerium für Bildung und Forschung (BMBF), No. 01 ZZ 0103.

Institutional review board statement: The study protocol was approved by the Ethics Committee of the University of Greifswald. The study was monitored by a review board of independent scientists.

Informed consent statement: All study participants provided informed consent prior to study enrollment.

Conflict-of-interest statement: The authors declare that they have no conflicts of interest.

Data sharing statement: Statistical code is available from the corresponding author. The data set can be requested from the Institute for Community Medicine, University Medicine Greifswald, 17489 Greifswald, Germany, under consideration of local data protection formalities.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Unsolicited manuscript

Correspondence to: Dr. Katharina Piontek, Dipl.-Psych., Institute for Medical Psychology, University Medicine Greifswald, Walther-Rathenau-Str. 48, 17489 Greifswald, Germany. katharina.piontek@uni-greifswald.de
Telephone: +49-3834-865696

Received: September 20, 2016

Peer-review started: September 24, 2016

First decision: November 21, 2016

Revised: March 20, 2017

Accepted: April 18, 2017

Article in press: April 20, 2017

Published online: July 8, 2017

Abstract

AIM

To investigate the association between hepatic steatosis and change in left ventricular mass index (LVMI) over five years, and examine whether systolic and diastolic blood pressures are mediators of the association between hepatic steatosis and LVMI using a general population sample.

METHODS

We analyzed data from the Study of Health in Pomerania. The study population comprised 1298

individuals aged 45 to 81 years. Hepatic steatosis was defined as the presence of a hyperechogenic pattern of the liver together with elevated serum alanine transferase levels. Left ventricular mass was determined echocardiographically and indexed to height^{2,7}. Path analyses were conducted to differentiate direct and indirect paths from hepatic steatosis to LVMI encompassing systolic and diastolic blood pressure as potential mediating variables.

RESULTS

Hepatic steatosis was a significant predictor for all measured echocardiographic characteristics at baseline. Path analyses revealed that the association of hepatic steatosis with LVMI change after five years was negligibly small ($\beta = -0.12$, s.e. = 0.21, $P = 0.55$). Systolic blood pressure at baseline was inversely associated with LVMI change ($\beta = -0.09$, s.e. = 0.03, $P < 0.01$), while no association between diastolic blood pressure at baseline and LVMI change was evident ($\beta = 0.03$, s.e. = 0.05, $P = 0.56$). The effect of the indirect path from hepatic steatosis to LVMI *via* systolic baseline blood pressure was small ($\beta = -0.20$, s.e. = 0.10, $P = 0.07$). No indirect effect was observed for the path *via* diastolic baseline blood pressure ($\beta = 0.03$, s.e. = 0.06, $P = 0.60$). Similar associations were observed in the subgroup of individuals not receiving beta-blockers, calcium channel blockers, or drugs acting on the renin-angiotensin system.

CONCLUSION

Baseline associations between hepatic steatosis and LVMI do not extend to associations with LVMI change after five years. More studies are needed to study the longitudinal effects of hepatic steatosis on LVMI.

Key words: Hepatic steatosis; Left ventricular mass index; Blood pressure; General Population; Study of Health in Pomerania

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Data regarding the association between hepatic steatosis and left ventricular remodeling are limited and previous studies revealed conflicting results. In the present study, hepatic steatosis as defined by liver hyperechogenicity and increased alanine transferase levels was a significant predictor for all measured echocardiographic characteristics at baseline. In contrast, hepatic steatosis was not a predictor of relevance for left ventricular mass index (LVMI) change. Systolic and diastolic blood pressures did not mediate the association between hepatic steatosis and LVMI.

INTRODUCTION

Hepatic steatosis is highly prevalent in Western countries and regarded as the hepatic manifestation of the metabolic syndrome^[1]. Results from previous studies indicate that the metabolic syndrome and its components such as overweight and hypertension are associated with an increase in left ventricular mass (LVM)^[2,3]. Data on the association between hepatic steatosis and LVM are limited; only four cross-sectional studies of small sample size exist addressing this relationship. The first study investigated the effect of hepatic steatosis on left ventricular geometry and function in normotensive, nondiabetic patients and demonstrated that patients with hepatic steatosis had mildly altered left ventricular geometry and early signs of left ventricular diastolic dysfunction compared to controls^[1]. The second study analyzed the relationship between left ventricular morphology, metabolic parameters and hepatic steatosis in patients with hypertension and revealed that individuals with hepatic steatosis had a similar prevalence of left ventricular hypertrophy (LVH) compared to individuals without hepatic steatosis^[4]. The third study using data from hypertensive, diabetic patients revealed that the frequency of LVH was higher in individuals with hepatic steatosis compared to individuals without hepatic steatosis. This study further showed that individuals with hepatic steatosis yielded 6-fold higher odds ratios for LVH than individuals without hepatic steatosis^[5]. The fourth study was of case-control design and demonstrated that hepatic steatosis was significantly associated with left ventricular dysfunction in diabetic patients^[6]. Due to the design of the aforementioned studies, inferences about effect directions between hepatic steatosis and left ventricular remodelling cannot be made. In particular, there is no differentiation between direct paths from hepatic steatosis to LVM progression or indirect effects *via* mediators. However, the evaluation of potential mediators is important for a better understanding of the mechanisms underlying a putative association between hepatic steatosis and LVM. We hypothesize that blood pressure is a potential key mediator on the path from hepatic steatosis to LVM as LVH is known to be the major cardiac sequel of hypertension^[7,8]. Thus, blood pressure should be adequately considered in studies aimed to investigate the association between hepatic steatosis and LVM.

To our knowledge, there is no previous research providing data on the association between hepatic steatosis and left ventricular mass index (LVMI) encompassing the following criteria: (1) using a general population sample; (2) using longitudinal data to improve inferences on the direction of effects; and (3)

Piontek K, Schmidt CO, Baumeister SE, Lerch MM, Mayerle J, Dörr M, Felix SB, Völzke H. Is hepatic steatosis associated with left ventricular mass index increase in the general population? *World J Hepatol* 2017; 9(19): 857-866 Available from: URL: <http://www.wjgnet.com/1948-5182/full/v9/i19/857.htm> DOI:




Figure 1 Flow-chart according to sample recruitment. ALT: Alanine transferase.

using methods to differentiate between direct and indirect pathways of hepatic steatosis on LVMI *via* blood pressure. The two major aims of the present study were, first, to investigate the association between hepatic steatosis and LVMI in a general population sample with prospective 5-year follow-up examination and, second, to analyze the mediating role of systolic and diastolic blood pressure on the pathway from hepatic steatosis to LVMI.

MATERIALS AND METHODS

Setting and study population

The Study of Health in Pomerania (SHIP) is a population-based cohort study conducted in West Pomerania, the northeastern area of Germany^[9]. The sample recruitment procedure is displayed in Figure 1. At baseline, a sample of 7008 individuals aged 20 to 79 years was drawn from population registries. Only individuals with German citizenship and main residency in the study area were included. The net sample (without migrated or deceased persons) comprised 6265 eligible individuals. Each individual received a maximum of three postal invitation letters. In case of non-response, letters were followed by a phone call or by home visits. The SHIP population finally comprised 4308

participants (response 68.8%). Baseline examinations were conducted between 1997 and 2001. Between 2002 and 2006, all participants were re-invited for an examination follow-up, in which 3300 individuals (83.5% of eligible persons) took part^[10]. Follow-up examinations were conducted on average 5.3 years after baseline (median: 5.0, 25th percentile: 5.0, 75th percentile: 5.3). All participants gave informed written consent. The study protocol was consistent with the principles of the Declaration of Helsinki and approved by the Ethics Committee of the University of Greifswald. The study was monitored by a review board of independent scientists.

Among the 3300 participants with follow-up data, only those aged 45 years and older underwent echocardiographic examination at baseline ($n = 1950$). Of these, 1548 participants received a second echocardiography at follow-up. Readable echocardiograms from both examinations were available for 1538 individuals. Among these, 185 echocardiograms were not evaluable, 22 individuals had an uncertain diagnosis of hepatic steatosis, five were tested positive for hepatitis B surface antigen, nine were tested positive for anti-hepatitis C virus antibody, and four had a self-reported history of liver cirrhosis. Furthermore, ten participants had missing data on serum alanine transferase (ALT), and 15 participants lacked blood pressure measurements. Exclusion of these participants resulted in a final study population of 1298 individuals for the present analyses.

Measurements

Baseline assessments included data on demographics, behavioural risk factors, the individual's medical history and medication as well as data from somatometric, sonographic, echocardiographic and laboratory examinations.

Data on demographics, behavioral risk factors such as physical activity, alcohol consumption, and smoking status were collected using computer-assisted personal interviews. The following demographic variables were assessed: Gender, age and school educational attainment (in years of schooling completed). Individuals who participated in physical training during summer or winter for at least one hour a week were classified as being physically active. Alcohol consumption was assessed using a beverage-specific quantity-frequency measure: Number of days with alcohol consumption (beer, wine, spirits), and the quantity of alcohol consumed on such a day over the last month. Average daily consumption (in grams of pure ethanol) was calculated by multiplying frequency and amount, using beverage specific standard ethanol contents^[11]. According to smoking habits, individuals were categorized into current, former, and never-smokers. Data on diabetes mellitus were obtained by self-reported physician's diagnosis of the disease.

The somatometric measures included body weight and height as well as waist circumference (WC). Height

and weight were measured for the calculation of the body mass index [BMI, weight (kg)/height² (m²)]. WC was measured to the nearest 0.1 cm using an inelastic tape midway between the lower rib margin and the iliac crest in the horizontal plane, with the subject standing comfortably with weight distributed evenly on both feet.

Systolic and diastolic blood pressure were measured between 8 am and 7 pm three times after an initial five minute rest period at the right arm of seated individuals using a digital blood pressure monitor (HEM-705CP, Omron Corporation, Tokyo, Japan). Each reading was followed by a further rest period of three minutes. One of two differently sized cuffs was applied according to the circumference of the participant's arm. The mean of the second and third measurement was calculated and used for the present analyses. Pulse pressure was defined as the difference between mean systolic and diastolic pressures. Hypertension was defined as systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg or use of antihypertensive medication.

For the laboratory examinations, non-fasting blood samples were drawn from the cubital vein in the supine position. The laboratory takes part quarterly in the official national German external proficiency testing programs. In addition, internal quality controls were analyzed daily. Hepatitis B surface antigen and anti-hepatitis C virus antibodies were determined by enzyme-linked immunosorbent assays (AxSym HBSAG and AxSym HCV, Abbot, Abbot Park, IL, United States). Serum ALT levels were measured photometrically (Hitachi 704; Roche, Mannheim, Germany) and expressed as $\mu\text{mol/L} \times \text{s}$, which corresponds to $(\mu\text{mol/L} \times \text{s}) \times 60 = \text{IU/L}$.

Sonographic examinations were performed by physicians using a 5 MHz transducer and a high resolution instrument (Vingmed VST Gateway, Santa Clara, CA, United States). The sonographers were unaware of the participants' clinical and laboratory characteristics. In SHIP, ultrasound examinations and readings underlie strict quality standards^[12]. Hepatic steatosis was defined as the presence of a hyperechogenic liver pattern, with evident density differences between hepatic and renal parenchyma^[13-15] together with increased serum ALT levels ($> 75^{\text{th}}$ percentile)^[16].

Two-dimensional and M-mode echocardiography was performed by trained physicians using a Vingmed CFM 800A system (GE Medical Systems, Waukesha, WI, United States). All data and measurements were stored digitally. M-mode images of the left ventricle were recorded at the papillary level. Left ventricular dimensions [interventricular septum thickness (IVS), posterior wall thickness (LVPW), and left ventricular end-diastolic diameter (LVDD)] were measured off-line using the leading edge convention. LVMI was calculated as follows: $\text{LVMI} = 0.80 \times \{1.04 \times [(\text{LVDD} + \text{IVS} + \text{LVPW})^3 - \text{LVDD}^3]\} + 0.60/\text{height}^{2.7[17,18]}$. LVH

was defined as a LVMI of $> 48 \text{ g/m}^{2.7}$ in men and $> 44 \text{ g/m}^{2.7}$ in women^[19]. Comparisons of intra-reader, intra-observer, inter-reader, and inter-observer LVMI measurements revealed Spearman coefficients of > 0.85 and differences in mean ($\pm 2 \text{ SD}$) of $< 5\%$ ($< 25\%$).

Statistical analysis

The study population was divided into two groups based on the presence or absence of liver hyperechogenicity and increased ALT levels at baseline: Category 1 comprised individuals without hyperechogenic liver pattern and without increased serum ALT levels and individuals fulfilling only one of the named criteria. Category 2 comprised individuals with hepatic steatosis as defined by both liver hyperechogenicity and increased serum ALT levels.

Using analyses of variance and χ^2 -statistics, differences in baseline characteristics between individuals with and without hepatic steatosis regarding demographics, behavioural risk factors, and clinical characteristics were analyzed. Changes in echocardiographic parameters and blood pressure are depicted using absolute numbers and percentages. Bivariate correlations were calculated based on Pearson correlation coefficients.

We conducted path analyses to evaluate direct effects of hepatic steatosis on LVMI and the indirect effects *via* systolic and diastolic blood pressure. Standardized regression coefficients for systolic and diastolic blood pressure as well as LVMI are presented in the figures. The χ^2 -value, comparative fit index (CFI), and the root mean square error (RMSEA) are provided as indicators of model fit. CFI is an incremental fit index comparing the fit of the model of interest with the independence model with values ranging from zero to one. RMSEA is a descriptive approximate estimation of the overall fit of the model in the population. Values have a lower bound of zero. A CFI > 0.96 and a RMSEA < 0.05 are commonly regarded as indicative of a satisfactory model fit^[20,21]. Parameter estimates were obtained based on a robust weighted least square approach (WLSMV), which is suitable to handle categorical and non-normal data^[21]. Age and sex were considered as independent predictors for all variables in the models. In addition, baseline body weight was included. LVMI was not regressed on body weight since body weight is part of the calculation of LVMI. The time of the day of blood pressure measurement was controlled for all indicators of blood pressure.

To evaluate possible bias due to missing data, we applied statistical inverse probability weights accounting for known individual characteristics of the study participants related to missing data on the echocardiographic examination at follow-up. These inverse probability weights were derived from logistic regression analyses with age, sex, body weight, waist circumference, alcohol intake, smoking, and a summative comorbidity index as predictors.

We repeated our analyses in the subgroup of indivi-

Table 1 General and echocardiographic characteristics of the study population with and without hepatic steatosis at baseline *n* (%)

	No/one criterion for hepatic steatosis <i>n</i> = 1106	US ⁺ and ALT ⁺ <i>n</i> = 192	<i>P</i> -value
Age (yr), M (SD)	59.6 (8.8)	57.2 (7.8)	<i>P</i> < 0.01
Male gender	442 (40.0)	139 (72.4)	<i>P</i> < 0.001
School education			n.s.
< 10 yr	570 (51.5)	102 (53.1)	
10 yr	358 (32.4)	67 (34.9)	
> 10 yr	178 (16.1)	23 (12.0)	
Waist circumference (cm), M (SD)	89.0 (11.5)	100.8 (10.9)	<i>P</i> < 0.001
Body weight (kg), M (SD)	75.6 (12.8)	88.6 (13.9)	<i>P</i> < 0.001
BMI, (kg/m ²), M (SD)	27.4 (4.3)	30.5 (4.6)	<i>P</i> < 0.001
Smoking			<i>P</i> < 0.001
Never-smoker	516 (46.6)	57 (29.7)	
Ex-smoker	382 (34.5)	99 (51.7)	
Current smoker	208 (18.8)	36 (18.8)	
Alcohol consumption (g/d), M (SD)	9.1 (14.5)	15.6 (19.5)	<i>P</i> < 0.001
Diabetes mellitus	100 (9.0)	26 (13.5)	<i>P</i> < 0.001
Systolic blood pressure (mmHg), M (SD)	139.3 (20.2)	148.5 (17.4)	<i>P</i> < 0.001
Diastolic blood pressure (mmHg), M (SD)	84.7 (10.8)	89.9 (10.4)	<i>P</i> < 0.001
Pulse pressure (mmHg), M (SD)	54.6 (14.7)	58.6 (13.4)	<i>P</i> < 0.01
Hypertension	660 (59.7)	163 (84.9)	<i>P</i> < 0.001
Intake of drugs with ATC07	239 (21.6)	39 (20.3)	n.s.
Intake of drugs with ATC08	140 (12.7)	28 (14.6)	n.s.
Intake of drugs with ATC09	198 (17.9)	58 (30.2)	<i>P</i> < 0.001
IVS, M (SD)	9.7 (2.2)	10.9 (2.5)	<i>P</i> < 0.001
LVEDD, M (SD)	50.9 (5.6)	52.4 (5.9)	<i>P</i> < 0.01
PWD, M (SD)	9.6 (1.9)	10.4 (2.0)	<i>P</i> < 0.001
LVM (g), M (SD)	181.8 (53.5)	215.8 (61.3)	<i>P</i> < 0.001
LVMI (g/m ^{2.7}), M (SD)	46.2 (13.3)	51.0 (13.7)	<i>P</i> < 0.001
LVH	499 (45.1)	114 (59.4)	<i>P</i> < 0.001

Pearson χ^2 and ANOVAs were used for bivariate comparisons. Data are given as numbers and percentages or means (standard deviation). US: Ultrasound; ALT: Alanine aminotransferase; ATC: Anatomical-therapeutic code; IVS: Interventricular septum thickness; LVEDD: Left ventricular end-diastolic diameter; PWD: Posterior wall thickness; LVMI: Left ventricular mass index; LVH: Left ventricular hypertrophy; n.s.: Non-significant.

duals not receiving medication with possible influence on LVM [beta-blockers, anatomical-therapeutic (ATC) codes C07; calcium channel blockers, ATC codes C08; and drugs acting on the renin-angiotensin system, ATC codes C09] as sensitivity analysis.

P values were estimated for two-sided tests. A value of *P* < 0.05 was considered statistically significant. Statistical analyses were performed using STATA 10.2 (Stata Corporation, College Station, TX, United States) to conduct descriptive statistics. MPLUS 5.1 (Muthén and Muthén, Los Angeles, CA, United States) was used for path analyses. Data analyses were performed by Carsten O Schmidt who is an expert in the field of biomedical statistics.

RESULTS

Sample characteristics

At baseline, 1106 (85.1%) individuals fulfilled no or one criterion for hepatic steatosis, while 192 (14.9%) individuals had hepatic steatosis as defined by the combined presence of hyperechogenic liver pattern and increased serum ALT levels. LVH was present in 48.3% of the study population. The mean LVMI was 49.8 g/m^{2.7} (SD = 14.7). General characteristics of the study population at baseline are presented in Table 1.

Baseline associations

Compared to individuals fulfilling no or one criterion for hepatic steatosis, individuals with hepatic steatosis were more often male, had lower educational attainment, a higher WC, a higher body weight, a higher BMI, were less often never-smokers and reported a higher average daily alcohol consumption. Moreover, individuals with hepatic steatosis reported more often diabetes mellitus, had higher systolic and diastolic blood pressure, higher pulse pressure and were more often hypertensive compared to individuals fulfilling no or one criterion for hepatic steatosis. Individuals with hepatic steatosis reported more often the intake of drugs acting on the renin-angiotensin system compared to the reference group. Regarding echocardiographic characteristics, individuals with hepatic steatosis showed a higher interventricular septum thickness, a higher posterior wall thickness, a higher left ventricular end-diastolic diameter, a higher left ventricular mass, a higher left ventricular mass index and more often left ventricular hypertrophy than the reference group.

Echocardiographic characteristics and blood pressure at baseline and follow-up

There was an increase in echocardiographic parameters from baseline to follow-up with higher values

Table 2 Echocardiographic characteristics and blood pressure at baseline and follow-up in the study population with and without hepatic steatosis

	Baseline M (SD)	Follow-up M (SD)	P-value
IVS, M (SD)			
No/one criterion for hepatic steatosis	9.7 (2.2)	11.2 (2.7)	$P < 0.001$
US ⁺ and ALT ⁺	10.9 (2.5)	12.0 (2.9)	$P < 0.001$
LVEDD, M (SD)			
No/one criterion for hepatic steatosis	50.9 (5.6)	48.8 (5.5)	$P < 0.001$
US ⁺ and ALT ⁺	52.4 (5.9)	50.6 (5.3)	$P < 0.001$
PWD, M (SD)			
No/one criterion for hepatic steatosis	9.6 (1.9)	9.9 (1.9)	$P < 0.001$
US ⁺ and ALT ⁺	10.4 (2.0)	10.9 (2.1)	$P < 0.01$
LVM (g), M (SD)			
No/one criterion for hepatic steatosis	181.8 (53.5)	192.2 (56.8)	$P < 0.001$
US ⁺ and ALT ⁺	215.8 (61.3)	226.1 (62.4)	$P < 0.01$
LVMI (g/m ^{2.7}), M(SD)			
No/one criterion for hepatic steatosis	46.2 (13.3)	49.2 (14.6)	$P < 0.001$
US ⁺ and ALT ⁺	51.0 (13.7)	53.7 (14.4)	$P < 0.01$
SBP (mmHg), M (SD)			
No/one criterion for hepatic steatosis	139.3 (20.2)	136.3 (19.2)	$P < 0.001$
US ⁺ and ALT ⁺	148.5 (17.4)	142.8 (19.0)	$P < 0.001$
DBP (mmHg), M (SD)			
No/one criterion for hepatic steatosis	84.7 (10.8)	81.2 (10.3)	$P < 0.001$
US ⁺ and ALT ⁺	89.9 (10.4)	85.0 (11.1)	$P < 0.001$
LVH			
No/one criterion for hepatic steatosis	499 (45.1)	597 (54.0)	$P < 0.001$
US ⁺ and ALT ⁺	114 (59.4)	128 (66.7)	$P < 0.001$
Hypertension			
No/one criterion for hepatic steatosis	660 (59.7)	686 (62.0)	$P < 0.001$
US ⁺ and ALT ⁺	163 (84.9)	154 (80.2)	$P < 0.001$

IVS: Interventricular septum thickness; LVEDD: Left ventricular end diastolic diameter; PWD: Posterior wall thickness; LVM: Left ventricular mass; LVMI: Left ventricular mass index; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; LVH: Left ventricular hypertrophy; US: Ultrasound; ALT: Alanine aminotransferase.

in individuals with hepatic steatosis compared to individuals fulfilling no or one criterion (Table 2). Blood pressure decreased from baseline to follow-up in both groups, while the proportion of hypertensive individuals slightly increased in the reference group and decreased in individuals with hepatic steatosis.

Cross-sectional correlations between hepatic steatosis, blood pressure and LVMI

Hepatic steatosis was significantly correlated with all variables in the path models, but effect sizes were small (standardized coefficients ranging from 0.11 to 0.17, Table 3). Baseline measures of LVMI and blood pressure were most closely related to their respective counterparts at follow-up. Systolic blood pressure was consistently more closely associated to LVMI than diastolic blood pressure.

Prediction of LVMI change

Figure 2 depicts the results of path analyses in the whole study population with systolic and diastolic blood pressure as potential mediators. The model fit was very good. Analyses revealed a very small, non-significant direct effect of baseline hepatic steatosis on LVMI change ($\beta = -0.12$, s.e. = 0.21, $P = 0.55$) and a negligible indirect effect *via* diastolic blood pressure ($\beta = 0.03$, s.e. = 0.06, $P = 0.60$, respectively). The

moderate indirect effect *via* systolic blood pressure was borderline significant ($\beta = -0.20$, s.e. = 0.10, $P = 0.07$). Systolic blood pressure at baseline was inversely associated with LVMI change ($\beta = -0.09$, s.e. = 0.03, $P < 0.01$), while no association between diastolic blood pressure at baseline and LVMI change was evident ($\beta = 0.03$, s.e. = 0.05, $P = 0.56$).

Repeating our analyses after excluding individuals not receiving beta-blockers, calcium channel blockers or drugs acting on the renin-angiotensin system revealed similar results (Figure 3).

We further repeated our analyses after excluding 30 individuals with high risk drinking according to the recommendations of the World Health Organization (consumption levels of 40 g/d in women and > 60 g/d in men). Analyses revealed almost identical results (direct effect of baseline hepatic steatosis on LVMI change: $\beta = -0.13$, s.e. = 0.21, $P = 0.54$).

DISCUSSION

To the best of our knowledge, the present study is the first to investigate the association between hepatic steatosis and change in LVMI and the mediating role of systolic and diastolic blood pressure in this association using data from a prospective population-based cohort. While we observed relevant baseline

Table 3 Bivariate Pearson correlations

	Sex	Age	FLD	LVMI ₀	LVMI ₁	SBP ₀	SBP ₁	DBP ₀
Sex								
Age	-0.04							
FLD	-0.23 ^b	-0.10 ^b						
LVMI ₀	-0.12 ^b	0.30 ^b	0.13 ^b					
LVMI ₁	-0.08 ^b	0.26 ^b	0.11 ^b	0.62 ^b				
SBP ₀	-0.21 ^b	0.24 ^b	0.16 ^b	0.36 ^b	0.24 ^b			
SBP ₁	-0.13 ^b	0.18 ^b	0.12 ^b	0.22 ^b	0.22 ^b	0.49 ^b		
DBP ₀	-0.20 ^b	-0.14 ^b	0.17 ^b	0.19 ^b	0.11 ^b	0.71 ^b	0.32 ^b	
DBP ₁	-0.15 ^b	-0.28 ^b	0.13 ^b	0.04	0.05	0.28 ^b	0.65 ^b	0.52 ^b

^b $P < 0.01$. FLD: Fatty liver disease; LVMI₀: Left ventricular mass index at baseline; LVMI₁: Left ventricular mass index at follow-up; SBP₀: Systolic blood pressure at baseline; SBP₁: Systolic blood pressure at follow-up; DBP₀: Diastolic blood pressure at baseline; DBP₁: Diastolic blood pressure at follow-up.




Figure 2 Path model for the effects of hepatic steatosis via systolic and diastolic blood pressure on left ventricular mass index in the whole study population ($n = 1298$). $\chi^2 = 3.2$, $df = 3$, $P = 0.36$; RMSEA < 0.01 ; CFI > 0.99 . Indirect Effect via BPsys0: $\beta = -0.20$; s.e. = 0.10; $P = 0.07$; Indirect Effect via BPdia0: $\beta = 0.03$; s.e. = 0.06; $P = 0.60$. FLD: Fatty liver disease; LVMI: Left ventricular mass index; BPsys: Systolic blood pressure; BPdia: Diastolic blood pressure; RMSEA: Root mean square error; CFI: Comparative fit index; s.e.: Standard error.




Figure 3 Path model for the effects of hepatic steatosis via systolic and diastolic blood pressure on left ventricular mass index in the subgroup of individuals without medication ($n = 811$). $\chi^2 = 1.9$, $df = 3$, $P = 0.60$; RMSEA < 0.01 ; CFI > 0.99 . Indirect Effect via BPsys0: $\beta = -0.30$; s.e. = 0.17; $P = 0.07$; Indirect Effect via BPdia0: $\beta = 0.15$; s.e. = 0.14; $P = 0.30$. FLD: Fatty liver disease; LVMI: Left ventricular mass index; BPsys: Systolic blood pressure; BPdia: Diastolic blood pressure; RMSEA: Root mean square error; CFI: Comparative fit index; s.e.: Standard error.

associations between hepatic steatosis, blood pressure and LVMI, these associations were not relevant in the prediction of LVMI change. Our analyses suggest that hepatic steatosis is no predictor of relevance for LVMI change over time.

Previously, only four studies addressed the association between hepatic steatosis and left ventricular morphology^[1,4-6]. These studies were of cross-sectional design, used data from small and inhomogeneous samples of patients and yielded conflicting results. The findings of the present study are in good agreement with results from the case-control study by Goland *et al.*^[1] demonstrating normotensive patients with hepatic steatosis to have larger intraventricular septum and posterior wall thickness and larger LVM than controls. In our study, LVM at baseline was 181.8 g in individuals fulfilling no or one criterion for hepatic steatosis and 215.8 g in individuals with hepatic steatosis. LVH was present in 45.1% of the individuals fulfilling no or only one criterion for hepatic steatosis and in 59.4% of the individuals with hepatic steatosis. Larger

differences were found in the study by Mantovani *et al.*^[5] analyzing data from hypertensive, diabetic patients with hepatic steatosis. In that study, 82% of the patients with hepatic steatosis had LVH, while the proportion was 18% in patients without hepatic steatosis. Furthermore, patients with hepatic steatosis yielded 6-fold higher odds ratios for LVH compared to patients without hepatic steatosis. In contrast to the cross-sectional findings of our study, Bonapace *et al.*^[6] demonstrated no significant differences between patients with hepatic steatosis and patients without hepatic steatosis regarding left ventricular mass. Fallo *et al.*^[4] reported a comparable prevalence of LVH in patients with and without hepatic steatosis. However, that study was performed in hypertensive inpatients, in which a high prevalence of both FLD and LVH has been reported^[4,22,23]. Therefore, the reported results cannot be directly compared with results from a general population sample.

Regarding longitudinal associations, we only found negligible direct effects of baseline hepatic steatosis

on LVMI change. We hypothesized that blood pressure is a mediating factor involved in the pathway from hepatic steatosis to LVMI as blood pressure has been found to be a major risk factor for left ventricular remodelling^[24,25]. Yet, we failed to demonstrate indirect effects from hepatic steatosis on LVMI change *via* systolic and diastolic blood pressure. Interestingly, we observed an inverse association between systolic blood pressure at baseline and change in LVMI after five years. This finding is in contrast to previous studies revealing that both systolic and diastolic blood pressure are important correlates of LVM, whereas systolic blood pressure has been found to be more closely related to LVM than diastolic blood pressure^[26]. Our data showed a drop in systolic and diastolic blood pressure from baseline to follow-up in the study sample, whereas this drop was more pronounced in individuals with hepatic steatosis than in individuals fulfilling no or one criterion for hepatic steatosis. We suppose that information on high blood pressure given by study physicians after baseline examination may have led to lifestyle modification or a rise in health consciousness in the study participants including the intake of blood pressure-lowering medication resulting in lower blood pressure at follow-up examination.

Regarding pharmacological interventions, treatment with antihypertensive drugs is indicated in the management of patients with cardiac hypertrophy, whereas the validity of data regarding the effects of antihypertensive medication on LVH regression is limited due to methodological weaknesses of existing studies^[27]. Drugs acting on the renin-angiotensin system, beta blockers, and calcium channel blockers have been shown to diminish left ventricular mass with different efficacy^[28]. In the present study population, 20.3% of the individuals with hepatic steatosis reported the intake of beta blockers, 14.6% the intake of calcium channel blockers and 20.3% the intake of drugs acting on the renin-angiotensin system. In addition to blood pressure lowering effects, these drugs may lead to LVMI regression^[29]. It might be assumed that the observed decrease in blood pressure in the present sample was attended by LVMI regression covering a potentially present association between hepatic steatosis and LVMI. Repeating our analyses after excluding individuals taking beta blockers, calcium channel blockers, and drugs acting on the renin-angiotensin system confirmed our results in general. This finding indicates that the use of the respective medication did not have an influence on the association between hepatic steatosis and LVMI in the entire population as these drugs may prevent further increase of LVM or support regression of LVH^[30,31].

Besides pharmacological treatment, lifestyle modification including weight loss and a reduction of alcohol and salt intake may contribute to LVH regression^[29]. The role of physical activity remains controversial. It has been demonstrated that regular physical activity is associated with lower blood pressure and reduced

cardiac remodeling, while exercise can also lead to the development of LVH^[32]. In hypertensive individuals, exercise may have a positive effect on cardiac remodelling with regression or prevention of LVH^[32].

With respect to alcohol consumption, analyses after excluding participants with high risk drinking did not change the results of our study. We therefore assume that alcohol consumption had no major role in the association between hepatic steatosis and LVMI. However, it needs to be considered that the number of individuals with high risk drinking was low and drinking above recommended levels is a risk factor for both hepatic steatosis and changes in cardiac structure.

In the present general population sample, both hepatic steatosis and LVH were highly prevalent stressing the public health relevance of these disease conditions in the general population.

Our study has several strengths, but also potential limitations that should be considered. Major strengths encompass the population-based longitudinal design, the large sample size and the high prevalence of hepatic steatosis and LVH in the study region^[13,33]. Further strengths encompass the ultrasound and laboratory methods to detect hepatic steatosis and the strict quality management by standardized protocols and certified staff^[9]. Limitations may arise from the inability to perform liver biopsy due to ethical concerns although known as the gold standard in the diagnosis of hepatic steatosis. Regarding methodological issues, path analyses allow for a useful differentiation of direct and indirect effects and therefore improve the interpretation of relationships among multiple variables. Limitations comprise potential selection bias due to selective drop out and initial non-response. However, previous analyses do not suggest a major effect on the outcomes under study^[10,34]. More measurement points covering a larger time interval might be needed to improve our inferences on direct and indirect effects. Limitations may further arise from the inability to perform liver biopsy due to ethical concerns although known as the gold standard in the diagnosis of hepatic steatosis.

We conclude that hepatic steatosis as defined by liver hyperechogenity and increased ALT levels was not a predictor of relevance for LVMI change after five years in the present population-based cohort of individuals aged 45 to 81 years. Nevertheless, both hepatic steatosis and LVH were highly prevalent in the present indicating the importance of both disease conditions in the general population and the necessity for risk factor reduction to avoid subsequent morbidity and mortality.

COMMENTS

Background

Hepatic steatosis is highly prevalent in Western countries and regarded as the hepatic manifestation of the metabolic syndrome. The metabolic syndrome and its components such as overweight and hypertension are associated with

an increase in left ventricular mass (LVM). Data on the association between hepatic steatosis and LVM are limited; only four cross-sectional studies of small sample size exist addressing this relationship. Due to the design of the aforementioned studies, inferences about effect directions between hepatic steatosis and left ventricular remodelling cannot be made. In particular, there is no differentiation between direct paths from hepatic steatosis to LVM progression or indirect effects via mediators.

Research frontiers

There is no previous research providing data on the association between hepatic steatosis and left ventricular mass index (LVMI) encompassing the following criteria: (1) using a general population sample; (2) using longitudinal data to improve inferences on the direction of effects; and (3) using methods to differentiate between direct and indirect pathways of hepatic steatosis on LVMI via blood pressure.

Innovations and breakthroughs

The present study is the first to investigate the association between hepatic steatosis and change in LVMI and the mediating role of systolic and diastolic blood pressure in this association using data from a prospective population-based cohort.

Applications

The authors conclude that hepatic steatosis as defined by liver hyperechogenicity and increased ALT levels was not a predictor of relevance for LVMI change after five years in the present population-based cohort of individuals aged 45 to 81 years. Nevertheless, both hepatic steatosis and LVH were highly prevalent in the present study population indicating the importance of both disease conditions in the general population and the necessity for risk factor reduction to avoid subsequent morbidity and mortality.

Peer-review

This is an interesting and well-written manuscript. This study investigated the association between hepatic steatosis and change in LVMI over 5 years in a study population of 1298 individuals aged 45 to 81 years. Hepatic steatosis was demonstrated to be a significant predictor for all measured echocardiographic characteristics at baseline but not for LVMI change.

REFERENCES

- Goland S, Shimoni S, Zornitzki T, Knobler H, Azoulay O, Lutaty G, Melzer E, Orr A, Caspi A, Malnick S. Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. *J Clin Gastroenterol* 2006; **40**: 949-955 [PMID: 17063117 DOI: 10.1097/01.mcg.0000225668.53673.e6]
- Kotsis V, Stabouli S, Toumanidis S, Tsigoulis G, Rizos Z, Trakateli C, Zakopoulos N, Sion M. Obesity and daytime pulse pressure are predictors of left ventricular hypertrophy in true normotensive individuals. *J Hypertens* 2010; **28**: 1065-1073 [PMID: 20411600 DOI: 10.1097/HJH.0b013e3283370e5e]
- de Simone G, Palmieri V, Bella JN, Celentano A, Hong Y, Oberman A, Kitzman DW, Hopkins PN, Arnett DK, Devereux RB. Association of left ventricular hypertrophy with metabolic risk factors: the HyperGEN study. *J Hypertens* 2002; **20**: 323-331 [PMID: 11821719 DOI: 10.1097/00004872-200202000-00024]
- Fallo F, Dalla Pozza A, Sonino N, Lupia M, Tona F, Federspil G, Ermani M, Catena C, Soardo G, Di Piazza L, Bernardi S, Bertolotto M, Pinamonti B, Fabris B, Sechi LA. Non-alcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in essential hypertension. *Nutr Metab Cardiovasc Dis* 2009; **19**: 646-653 [PMID: 19278843 DOI: 10.1016/j.numecd.2008.12.007]
- Mantovani A, Zoppini G, Targher G, Golia G, Bonora E. Non-alcoholic fatty liver disease is independently associated with left ventricular hypertrophy in hypertensive Type 2 diabetic individuals. *J Endocrinol Invest* 2012; **35**: 215-218 [PMID: 22490991 DOI: 10.1007/BF03345421]
- Bonapace S, Perseghin G, Molon G, Canali G, Bertolini L, Zoppini G, Barbieri E, Targher G. Nonalcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes. *Diabetes Care* 2012; **35**: 389-395 [PMID: 22210573 DOI: 10.1007/BF03345421]
- Kannel WB, Gordon T, Offutt D. Left ventricular hypertrophy by electrocardiogram. Prevalence, incidence, and mortality in the Framingham study. *Ann Intern Med* 1969; **71**: 89-105 [PMID: 4239887 DOI: 10.7326/0003-4819-71-1-89]
- Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. *N Engl J Med* 1990; **322**: 1561-1566 [PMID: 2139921 DOI: 10.1056/NEJM199005313222203]
- Völzke H, Alte D, Schmidt CO, Radke D, Lörbe R, Friedrich N, Aumann N, Lau K, Piontek M, Born G, Havemann C, Ittermann T, Schipf S, Haring R, Baumeister SE, Wallaschofski H, Nauck M, Frick S, Arnold A, Jünger M, Mayerle J, Kraft M, Lerch MM, Dörr M, Reffelmann T, Empen K, Felix SB, Obst A, Koch B, Gläser S, Ewert R, Fietze I, Penzel T, Dören M, Rathmann W, Haerting J, Hannemann M, Röpcke J, Schminke U, Jürgens C, Tost F, Rettig R, Kors JA, Ungerer S, Hegenscheid K, Kühn JP, Kühn J, Hosten N, Puls R, Henke J, Gloger O, Teumer A, Homuth G, Völker U, Schwahn C, Holtfreter B, Polzer I, Kohlmann T, Grabe HJ, Roskopf D, Kroemer HK, Kocher T, Biffar R, John U, Hoffmann W. Cohort profile: the study of health in Pomerania. *Int J Epidemiol* 2011; **40**: 294-307 [PMID: 20167617 DOI: 10.1093/ije/dyp394]
- Haring R, Alte D, Völzke H, Sauer S, Wallaschofski H, John U, Schmidt CO. Extended recruitment efforts minimize attrition but not necessarily bias. *J Clin Epidemiol* 2009; **62**: 252-260 [PMID: 18834716 DOI: 10.1016/j.jclinepi.2008.06.010]
- Bühringer G, Augustin R, Bergmann E, Bloomfield K, Funk W, B. J. Alkoholkonsum und Alkoholbezogene Störungen in Deutschland [Alcohol consumption and alcohol-related problems in Germany]. Baden-Baden: Nomos Verlagsgesellschaft, 2000
- Lüdemann J, Piek M, Wood WG, Meyer S, Greiner B, John U, Hense HW. [Methods for quality assurance of medical examination in epidemiological field studies: the "Study of Health in Pomerania" (SHIP)]. *Gesundheitswesen* 2000; **62**: 234-243 [PMID: 10844821 DOI: 10.1055/s-2000-10857]
- Völzke H, Robinson DM, Kleine V, Deutscher R, Hoffmann W, Ludemann J, Schminke U, Kessler C, John U. Hepatic steatosis is associated with an increased risk of carotid atherosclerosis. *World J Gastroenterol* 2005; **11**: 1848-1853 [PMID: 15793879 DOI: 10.3748/wjg.v11.i12.1848]
- Bellentani S, Tiribelli C. The spectrum of liver disease in the general population: lesson from the Dionysos study. *J Hepatol* 2001; **35**: 531-537 [PMID: 11682041 DOI: 10.1016/S0168-8278(01)00151-9]
- Völzke H, Schwarz S, Baumeister SE, Wallaschofski H, Schwahn C, Grabe HJ, Kohlmann T, John U, Dören M. Menopausal status and hepatic steatosis in a general female population. *Gut* 2007; **56**: 594-595 [PMID: 17369390 DOI: 10.1136/gut.2006.115345]
- Baumeister SE, Völzke H, Marschall P, John U, Schmidt CO, Flessa S, Alte D. Impact of fatty liver disease on health care utilization and costs in a general population: a 5-year observation. *Gastroenterology* 2008; **134**: 85-94 [PMID: 18005961 DOI: 10.1053/j.gastro.2007.10.024]
- Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. *Am J Cardiol* 1986; **57**: 450-458 [PMID: 2936235 DOI: 10.1016/0002-9149(86)90771-X]
- Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography,

- a branch of the European Society of Cardiology. *J Am Soc Echocardiogr* 2005; **18**: 1440-1463 [PMID: 16376782 DOI: 10.1016/j.echo.2005.10.005]
- 19 **Abs R**, Bengtsson BA, Hernberg-Ståhl E, Monson JP, Tauber JP, Wilton P, Wüster C. GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety. *Clin Endocrinol (Oxf)* 1999; **50**: 703-713 [PMID: 10468941 DOI: 10.1046/j.1365-2265.1999.00695.x]
 - 20 **Hu L-tB**, Peter M. Cutoff Criteria for Fit Indexes in Covariance Structure Analysis: Conventional Criteria versus New Alternatives. *Structural Equation Modeling* 1999; **6**: 1-55 [DOI: 10.1080/10705519909540118]
 - 21 **Yu CY**. Evaluating Cutoff Criteria of Model Fit Indices for Latent Variable Models With Binary and Continuous Outcomes. Doctoral Thesis. Los Angeles: University of California, 2002
 - 22 **Donati G**, Stagni B, Piscaglia F, Venturoli N, Morselli-Labate AM, Rasciti L, Bolondi L. Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. *Gut* 2004; **53**: 1020-1023 [PMID: 15194655 DOI: 10.1136/gut.2003.027086]
 - 23 **Korner PI**, Jennings GL. Assessment of prevalence of left ventricular hypertrophy in hypertension. *J Hypertens* 1998; **16**: 715-723 [PMID: 9663910 DOI: 10.1097/00004872-199816060-00001]
 - 24 **Levy D**, Anderson KM, Savage DD, Kannel WB, Christiansen JC, Castelli WP. Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. *Ann Intern Med* 1988; **108**: 7-13 [PMID: 2962527 DOI: 10.7326/0003-4819-108-1-7]
 - 25 **Schirmer H**, Lunde P, Rasmussen K. Prevalence of left ventricular hypertrophy in a general population; The Tromsø Study. *Eur Heart J* 1999; **20**: 429-438 [PMID: 10213346 DOI: 10.1053/euhj.1998.1314]
 - 26 **Verdecchia P**, Angeli F, Gattobigio R, Guerrieri M, Benemio G, Porcellati C. Does the reduction in systolic blood pressure alone explain the regression of left ventricular hypertrophy? *J Hum Hypertens* 2004; **18** Suppl 2: S23-S28 [PMID: 15592569 DOI: 10.1038/sj.jhh.1001797]
 - 27 **Cuspidi C**, Esposito A, Negri F, Sala C, Masaidi M, Giudici V, Zanchetti A, Mancia G. Studies on left ventricular hypertrophy regression in arterial hypertension: a clear message for the clinician? *Am J Hypertens* 2008; **21**: 458-463 [PMID: 18369363 DOI: 10.1038/ajh.2007.85]
 - 28 **Frohlich ED**, González A, Díez J. Hypertensive left ventricular hypertrophy risk: beyond adaptive cardiomyocytic hypertrophy. *J Hypertens* 2011; **29**: 17-26 [PMID: 21045723 DOI: 10.1097/HJH.0b013e328340d787]
 - 29 **Sheridan DJ**, Kingsbury MP, Flores NA. Regression of left ventricular hypertrophy; what are appropriate therapeutic objectives? *Br J Clin Pharmacol* 1999; **47**: 125-130 [PMID: 10190646 DOI: 10.1046/j.1365-2125.1999.00871.x]
 - 30 **Ruggenenti P**, Iliev I, Costa GM, Parvanova A, Perna A, Giuliano GA, Motterlini N, Ene-Iordache B, Remuzzi G. Preventing left ventricular hypertrophy by ACE inhibition in hypertensive patients with type 2 diabetes: a prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT). *Diabetes Care* 2008; **31**: 1629-1634 [PMID: 18443191 DOI: 10.2337/dc08-0371]
 - 31 **Trimarco B**, De Luca N, Cuocolo A, Ricciardelli B, Rosiello G, Lembo G, Volpe M. Beta blockers and left ventricular hypertrophy in hypertension. *Am Heart J* 1987; **114**: 975-983 [PMID: 2889345 DOI: 10.1016/0002-8703(87)90596-5]
 - 32 **Hegde SM**, Solomon SD. Influence of Physical Activity on Hypertension and Cardiac Structure and Function. *Curr Hypertens Rep* 2015; **17**: 77 [PMID: 26277725 DOI: 10.1007/s11906-015-0588-3]
 - 33 **Völzke H**, Stritzke J, Kuch B, Schmidt CO, Lüdemann J, Döring A, Schunkert H, Hense HW. Regional differences in the prevalence of left ventricular hypertrophy within Germany. *Eur J Cardiovasc Prev Rehabil* 2009; **16**: 392-400 [PMID: 19369877 DOI: 10.1097/HJR.0b013e32832a4dc1]
 - 34 **Schmidt CO**, Alte D, Völzke H, Sauer S, Friedrich N, Valliant R. Partial misspecification of survey design features sufficed to severely bias estimates of health-related outcomes. *J Clin Epidemiol* 2011; **64**: 416-423 [PMID: 20926255 DOI: 10.1016/j.jclinepi.2010.04.019]

P- Reviewer: Losano G, Marzuillo P, Vespasiani-Gentilucci U

S- Editor: Kong JX **L- Editor:** A **E- Editor:** Li D





Published by **Baishideng Publishing Group Inc**
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>

